Ostarine Peptide Context (Selective Androgen Receptor Modulator overlap)
Ostarine (MK-2866 / enobosarm) is a selective androgen receptor modulator (SARM), a small molecule, not a peptide.
Overview
Ostarine, also known as MK-2866 or enobosarm, is a selective androgen receptor modulator (SARM), a class of non-steroidal small molecules, not a peptide. The Peptide Context label in the listing reflects catalog overlap between performance-oriented categories rather than chemistry. Ostarine was developed by GTx and was studied in clinical trials for cancer cachexia and muscle wasting, with evidence of lean-mass preservation, but it has not received regulatory approval.
Mechanism
SARMs bind the androgen receptor with tissue-selective effects, favoring anabolic actions in muscle and bone while showing reduced activity in some androgen-sensitive tissues relative to classical steroids. The precise selectivity differs among compounds in the class and is the subject of ongoing research.
Dosing
Published clinical trials used daily oral doses, generally in the low milligram range, specified per protocol. There is no approved dose, and unregulated products of unknown potency are a documented public-health concern, including association with failed drug tests and liver injury case reports.
Expected Effects
- preservation of lean body mass in some clinical trials in wasting conditions
- reductions in markers of catabolism in trial populations
- performance-related use is off-label and unsupported by approved indications
Side Effects & Tolerability
In trials, common effects included mild testosterone suppression, changes in lipids, and liver-enzyme elevations; case reports linked to unregulated use describe more serious liver injury. Hormonal suppression and the lack of quality control in black-market products are significant concerns.
Storage
Ostarine is an oral small molecule; research-grade material should be stored per the supplier label, typically cool, dry, and protected from light.